Background: Cases with sepsis after transrectal ultrasound-guided prostate biopsy (TRUSPB) were documented, with special focus on cultures and susceptibility of isolates. We also evaluated the contribution of concomitant rectal cultures to the treatment of selective cases. Materials and Methods: Patients with sepsis after TRUSPB were followed prospectively. Manifestations and risk factors for antimicrobial resistance were documented. Results of urine and blood cultures and antimicrobial susceptibility were recorded for all participating patients. In 40 patients, rectal swab cultures were obtained concomitantly. Results: Ninety-five patients were consecutively studied. Sepsis symptoms started showing up within 48 h after biopsy in 93% of patients. At least one of the cultures was positive in 72 patients. E. coli grew in 70 cases; isolates were highly resistant: 67% displayed multidrug-resistance. Rectal cultures grew E. coli in 38 cases. In patients with positive E. coli in rectum and in at least one additional culture (blood and/or urine), the antibiogram was identical in all cases but one. Eight cases had negative cultures. Conclusion: The prevalence of antimicrobial resistance among E. coli isolates from patients with TRUSPB sepsis was alarming. Susceptibilities of rectal E. coli isolates used for deescalation of initial empiric treatment in culture-negative TRUSPB sepsis can contribute to the reduction of broad-spectrum antibiotics exposure.

Keywords:
Antibacterial resistance, E. coli, Rectal cultures, Sepsis, Transrectal ultrasound-guided prostate biopsy
1.
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-968.
2.
Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002;60:826-830.
3.
Tal R, Livne PM, Lask DM, Baniel J: Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003;169:1762-1765.
4.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM: Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-1834.
5.
Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al: Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013;63:521-527.
6.
Aron M, Rajeev TP, Gupta NP: Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682-685.
7.
Zani EL, Clark OA, Rodrigues Netto N Jr: Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011;5:CD006576.
8.
Shandera KC, Thibault GP, Deshon GE Jr: Variability in patient preparation for prostate biopsy among American urologists. Urology 1998;52:644-646.
9.
Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pépin J: Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 2012;62:453-459.
10.
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS: Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011;77:1035-1041.
11.
Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al: The incidence of fluoroquinolone resistant infections after prostate biopsy - are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-955; discussion 955.
12.
Briffaux R, Coloby P, Bruyere F, Ouaki F, Pires C, Doré B, et al: One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 2009;103:1069-1073; discussion 1073.
13.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-281.
14.
Batura D, Rao GG, Nielsen PB: Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010;106:1017-1020.
15.
Bratzler DW, Houck PM: Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706-1715.
16.
Harbarth S, Samore MH, Lichtenberg D, Carmeli Y: Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916-2921.
17.
Bell D: Controversies in the prevention and control of antimicrobial drug resistance. Emerg Infect Dis 1998;4:473-474.
18.
Sabbagh R, McCormack M, Péloquin F, Faucher R, Perreault JP, Perrotte P, et al: A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol 2004;11:2216-2219.
19.
Shigemura K, Tanaka K, Yasuda M, Ishihara S, Muratani T, Deguchi T, et al: Efficacy of 1-day prophylaxis medication with fluoroquinolone for prostate biopsy. World J Urol 2005;23:356-360.
20.
Schjørring S, Struve C, Krogfelt KA: Transfer of antimicrobial resistance plasmids from Klebsiella pneumoniae to Escherichia coli in the mouse intestine. J Antimicrob Chemother 2008;62:1086-1093.
21.
Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al: Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012;187:1275-1279.
22.
Minamida S, Satoh T, Tabata K, Kimura M, Tsumura H, Kurosaka S, et al: Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology 2011;78:1235-1239.
23.
Mosharafa AA, Torky MH, El Said WM, Meshref A: Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011;78:511-514.
24.
Akduman B, Akduman D, Tokgöz H, Erol B, Türker T, Ayoğlu F, et al: Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011;78:250-255.
25.
Lee JW, Park SC, Kim MK, Cheon MW, Kim GY, Cho JH: Prevalence of antimicrobial resistance in normal rectal flora of patients undergoing transrectal ultrasonography-guided prostate biopsy in Korea. Int J Urol 2014;21:811-814.
26.
World Health Organization (WHO). Antimicrobial Resistance: Global Report on Surveillance, 2014. Geneva: WHO 2014.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.